CLEC5A mediated activation of the EMT signaling pathway in 35% of cancers, while CLEC5A mediated inhibition of DNA damage response and hormone AR pathway in 18% and 25% of cancers, respectively. The gene discussed is CLEC5A; the disease is cancer.